TY - JOUR
T1 - Prognostic role of tumoral PDL1 expression and peritumoral FoxP3+ lymphocytes in vulvar melanomas
AU - Chłopik, Agata
AU - Selim, M. Angelica
AU - Peng, Yan
AU - Wu, Cheng Lin
AU - Tell-Marti, Gemma
AU - Paral, Kristen M.
AU - Shalin, Sara C.
AU - Kraft, Stefan
AU - Hsu, Chao-Kai
AU - Shea, Christopher R.
AU - Puig, Susana
AU - Fernandez-Figueras, Maria Teresa
AU - Biernat, Wojciech
AU - Ryś, Janusz
AU - Marszalek, Andrzej
AU - Hoang, Mai P.
N1 - Publisher Copyright:
© 2018
PY - 2018/3
Y1 - 2018/3
N2 - The prognostic role of PDL1 expression, CD8+ and FoxP3+ lymphocytes in vulvar melanomas has not been studied. We correlated PDL1 expression and CD8+ and FoxP3+ immune infiltrates with clinicopathologic variables and patient outcomes in a series of 75 vulvar melanomas. Tumoral PDL1 expression (>5%) was seen in 23% of cases. By Fisher exact test, PDL1 expression and peritumoral FoxP3+ lymphocytes significantly correlated with less disease-specific death. By linear regression analysis, correlations between tumoral PDL1 expression with the density of tumoral CD8+ and peritumoral CD8+ lymphocytes, tumoral FoxP3+ with tumoral CD8+ lymphocytes, and peritumoral FoxP3+ with peritumoral CD8+ lymphocytes were observed. By univariate analyses, tumor thickness >4 mm predicted poorer progression-free survival, melanoma-specific survival, and overall survival. PDL1 expression >5% and peritumoral CD8+, peritumoral FoxP3+, and tumoral FoxP3+ lymphocytes correlated with better overall survival. By multivariate analyses, high peritumoral FoxP3+ lymphocytes independently predicted better melanoma-specific survival (P =.023), and tumor thickness independently predicted poorer progression-free survival (P =.05) and overall survival (P =.039). In conclusion, our study shows that, independent from tumor thickness, an increased density of peritumoral FoxP3+ lymphocytes may positively impact survival in a subset of vulvar melanomas. Tumoral PDL1 expression correlated with tumoral as well as peritumoral CD8+ and FoxP3+ lymphocytes, supportive of an adaptive immune response. Although the frequency of PDL1 expression is low in vulvar melanoma, its expression may identify a subset of vulvar melanoma that might respond to immunotherapy.
AB - The prognostic role of PDL1 expression, CD8+ and FoxP3+ lymphocytes in vulvar melanomas has not been studied. We correlated PDL1 expression and CD8+ and FoxP3+ immune infiltrates with clinicopathologic variables and patient outcomes in a series of 75 vulvar melanomas. Tumoral PDL1 expression (>5%) was seen in 23% of cases. By Fisher exact test, PDL1 expression and peritumoral FoxP3+ lymphocytes significantly correlated with less disease-specific death. By linear regression analysis, correlations between tumoral PDL1 expression with the density of tumoral CD8+ and peritumoral CD8+ lymphocytes, tumoral FoxP3+ with tumoral CD8+ lymphocytes, and peritumoral FoxP3+ with peritumoral CD8+ lymphocytes were observed. By univariate analyses, tumor thickness >4 mm predicted poorer progression-free survival, melanoma-specific survival, and overall survival. PDL1 expression >5% and peritumoral CD8+, peritumoral FoxP3+, and tumoral FoxP3+ lymphocytes correlated with better overall survival. By multivariate analyses, high peritumoral FoxP3+ lymphocytes independently predicted better melanoma-specific survival (P =.023), and tumor thickness independently predicted poorer progression-free survival (P =.05) and overall survival (P =.039). In conclusion, our study shows that, independent from tumor thickness, an increased density of peritumoral FoxP3+ lymphocytes may positively impact survival in a subset of vulvar melanomas. Tumoral PDL1 expression correlated with tumoral as well as peritumoral CD8+ and FoxP3+ lymphocytes, supportive of an adaptive immune response. Although the frequency of PDL1 expression is low in vulvar melanoma, its expression may identify a subset of vulvar melanoma that might respond to immunotherapy.
UR - http://www.scopus.com/inward/record.url?scp=85042188109&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042188109&partnerID=8YFLogxK
U2 - 10.1016/j.humpath.2017.12.022
DO - 10.1016/j.humpath.2017.12.022
M3 - Article
C2 - 29307625
AN - SCOPUS:85042188109
SN - 0046-8177
VL - 73
SP - 176
EP - 183
JO - Human Pathology
JF - Human Pathology
ER -